

## 13\_Prevention

May 18, 2018 (Friday)

10:30-12:00

1

### Health Care Policy in Cardiovascular Disease Prevention

**Chair 1:** TBA

**Chair 2:** TBA

Time **Topic 1** Cardiovascular Disease Prevention in Thailand  
**Prasart Laothavorn (Thailand)**

Time **Topic 2** Cardiovascular Disease Prevention in Taiwan  
**TBA**

Time **Topic 3** Cardiovascular Disease Prevention in Australia  
**TBA**

Time **Topic 4** Cardiovascular Disease Prevention in Japan  
**TBA**

13:30-15:00

2

### Obesity as a Cardiovascular Disease Burden

**Chair 1:** TBA

**Chair 2:** TBA

20 **Topic 1** Current Status and Management Strategy of Obesity in Asia  
**TBA**

Time **Topic 2** Central Obesity and Body Mass Index: Impact on Cardiovascular Disease in Asia  
**TBA**

Time **Topic 3** Bariatric Surgery Outcome, Fact or Fiction?  
**TBA**

Time **Topic 4** Pharmacological Intervention  
**TBA**

15:30-17:00

3

### Controversial Therapy for Dyslipidemia Management (ISCP Joint Session)

**Chair 1:** TBA

**Chair 2:** TBA

Time **Topic 1** The Priority of Targets  
**TBA**

Time **Topic 2** Strategy for Facing Aging Society  
**TBA**

Time **Topic 3** The Role of Omega-3 Fatty Acid  
**TBA**

Time **Topic 4** Management of Residual Risks  
**TBA**

**May 19, 2018 (Saturday)**

**08:30-10:00**

**4**

**Environmental Pollution and Cardiovascular Disease**

**Chair 1:** TBA

**Chair 2:** TBA

Time	<b>Topic 1</b>	Air Pollution and Cardiovascular Disease <b>TBA</b>
Time	<b>Topic 2</b>	Risk of Dust-haze in Cardiovascular Disease <b>TBA</b>
Time	<b>Topic 3</b>	Endocrine Disrupting Chemicals and Cardiovascular Health <b>TBA</b>
Time	<b>Topic 4</b>	Cardiovascular Benefit of Pharmacological Treatments for Smoking Cessation <b>TBA</b>

**10:30-12:00**

**5**

**Risk Stratification in Cardiovascular Diseases (ACC in Taiwan)**

**Chair 1:** TBA

**Chair 2:** TBA

Time	<b>Topic 1</b>	Risk Stratification of Coronary Artery Disease in Taiwan <b>TBA</b>
Time	<b>Topic 2</b>	USA Pooled Cohort Equations to Predict 1-year Risk for Atherosclerotic Cardiovascular Disease Events <b>TBA</b>
Time	<b>Topic 3</b>	Framingham Risk Score, What's New? <b>TBA</b>
Time	<b>Topic 4</b>	Is QRISK"2 & 3" Applicable in Asian Population? <b>TBA</b>

**13:30-15:00**

**6**

**New Era in Pharmacological Treatment of Atherosclerotic Disease**

**Chair 1:** TBA

**Chair 2:** TBA

Time	<b>Topic 1</b>	PCSK9 Inhibition for High Risk ASCVD Patients <b>TBA</b>
Time	<b>Topic 2</b>	CETP Inhibition in ASCVD <b>TBA</b>
Time	<b>Topic 3</b>	Optimal Therapy for Familial Hyperlipidemia <b>TBA</b>
Time	<b>Topic 4</b>	Epigenetic Modification in ASCVD <b>TBA</b>

15:30-17:00

7

**Rehabilitation and Exercise**

**Chair 1:** TBA

**Chair 2:** TBA

Time	<b>Topic 1</b>	Cardiac Rehabilitation in Coronary Artery Disease <b>TBA</b>
Time	<b>Topic 2</b>	Cardiac Rehabilitation in Heart Failure <b>TBA</b>
Time	<b>Topic 3</b>	Cardiac Evaluation of Athletes in Taipei 2017 Summer Universiade <b>Lung-Chun Lin (Taiwan)</b>
Time	<b>Topic 4</b>	Benefit of Exercise on Cardiovascular Disease <b>TBA</b>

**May 20, 2018 (Sunday)**

08:30-10:00

8

**Dyslipidemia Management in Asia**

**Chair 1:** TBA

**Chair 2:** TBA

Time	<b>Topic 1</b>	Update of Dyslipidemia Guideline in Taiwan <b>TBA</b>
Time	<b>Topic 2</b>	Current Status of Lipid Control in Australia <b>TBA</b>
Time	<b>Topic 3</b>	Current Status of Lipid Control in Malaysia <b>TBA</b>
Time	<b>Topic 4</b>	Is TG Important for Asians? <b>TBA</b>